soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized NEJM Editorial Fellow Harleen Marwah,
Pay in 4 interest-free payments of $7.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9


























